MedTrace Logo

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

NCT05489640 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2024-08-05

No results posted yet for this study

Summary

The main aim of this study is to describe the treatment patterns, characteristics and outcomes of people with HAE who are currently receiving icatibant in the homecare setting in the United Kingdom (UK).

Participants will be treated with icatibant according to their routine practice via homecare service for icatibant within the UK. Data will be directly collected from participants via study diaries and questionnaires. Participants will be contacted approximately every 90 days during study duration (this can occur via phone or as a face-to-face visit).

Conditions

  • Hereditary Angioedema (HAE)

Interventions

OTHER

No Intervention

No Intervention will be administered in this study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-18
Primary Completion
2024-07-17
Completion
2024-07-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05489640 on ClinicalTrials.gov